NovoCure Competitors and Similar CompaniesClear all

Lyell's competitors and similar companies include Silverback Therapeutics, Accuray, Zymeworks and Legend Biotech.

	Lyell Lyell Immunopharma is a T-cell reprogramming company to cure patients with solid tumors.	Silverback Therapeutics Silverback Therapeutics is a biotech company developing treatments for cancer, fibrosis, and infectious diseases.	Accuray Accuray is a radiation therapy company that develops, manufactures, sells, and supports radiation treatment solutions.	Zymeworks Zymeworks is a computational biotechnology company focused on optimizing therapeutic antibodies and other protein-based therapeutics.	Legend Biotech Legend Biotech is a biopharmaceutical company engaged in the discovery and development of cell therapies for oncology and other indications.
Founding Date	Founding Date 2018	Founding Date 2016	Founding Date 1990	Founding Date 2003	Founding Date 2014
Type	Type Public	Type Public	Type Public	Type Public	Type Public
Tags	Tags Healthcare biotech oncology platform therapy	Tags Healthcare biotech oncology therapy	Tags Manufacturing & Industrial medical devices medtech oncology therapy	Tags Healthcare biotech oncology therapy	Tags Healthcare biotech oncology pharma therapy
Locations	Locations South San Francisco, US HQ Bothell, US Seattle, US	Locations Seattle, US HQ	Locations Madison, US HQ Chengdu, CN Kowloon, HK Tokyo, JP Morges, CH Santa Clara, US Sunnyvale, US	Locations Vancouver, CA HQ Seattle, US	Locations Somerset, US HQ Ghent, BE Nanjing, CN Hong Kong, HK Dublin, IE Piscataway, US
Employees	Employees 188	Employees 9067% increase	Employees 9874% decrease	Employees 45519% increase	Employees 2,90012% increase
Valuation ($)	Valuation ($) 243.3 m	Valuation ($) 550.4 m	Valuation ($) 186.5 m	Valuation ($) 973.3 m	Valuation ($) 8.4 b
Financial
Revenue (est.)	Revenue (est.) $36k (FY, 2025)	Revenue (est.) $1.3m (FY, 2022)	Revenue (est.) $458.5m (FY, 2025)	Revenue (est.) $106m (FY, 2025)	Revenue (est.) $1b (FY, 2025)
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods $311.5m (FY, 2025)	Cost of goods N/A	Cost of goods $408.1m (FY, 2025)
Gross profit	Gross profit N/A	Gross profit N/A	Gross profit $147m (FY, 2025)	Gross profit N/A	Gross profit $620.8m (FY, 2025)
Net income	Net income ($274.4m) (FY, 2025)	Net income ($34.7m) (FY, 2022)	Net income ($1.6m) (FY, 2025)	Net income ($81.1m) (FY, 2025)	Net income ($296.8m) (FY, 2025)
Funding
Total funding raised	Total funding raised N/A	Total funding raised $ 211m	Total funding raised N/A	Total funding raised $ 125.9m	Total funding raised $ 150.5m